Amendment: SEC Form SC 13G/A filed by Alkermes plc
$ALKS
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | $25.00 → $36.00 | Hold → Buy | Stifel |
| 6/17/2024 | $34.00 | Buy | TD Cowen |
| 3/19/2024 | $37.00 | Outperform | Robert W. Baird |
| 2/20/2024 | $25.00 | Neutral → Sell | UBS |
| 11/20/2023 | $33.00 | Neutral | JP Morgan |
| 10/24/2023 | In-line → Outperform | Evercore ISI | |
| 10/17/2023 | $31.00 | Neutral | UBS |
| 11/3/2022 | $26.00 → $30.00 | Neutral → Overweight | Piper Sandler |
SC 13G - Alkermes plc. (0001520262) (Subject)
SC 13G/A - Alkermes plc. (0001520262) (Subject)
SC 13G/A - Alkermes plc. (0001520262) (Subject)
4 - Alkermes plc. (0001520262) (Issuer)
4 - Alkermes plc. (0001520262) (Issuer)
4 - Alkermes plc. (0001520262) (Issuer)
DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern
NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t
— Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business — — Planned Separation Remains on Track to be Completed in Second Half of 2023 — DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation. "Dr. Loew's deep knowledge of the oncology fi
— Third Quarter Revenues of $378.1 Million — — Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $92.8 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.56 — — Company Reiterates 2024 Financial Expectations — DUBLIN, Oct. 24, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the third quarter of 2024. "Our third quarter financial results reflect strong year-over-year growth of our portfolio of proprietary commercial products and position us well to meet our strategic, operational and financial priorities for the year. Looking ahead, we believe growing our
DUBLIN, Oct. 17, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Thursday, Oct. 24, 2024 to discuss the company's third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website. About Alkermes plcAlkermes plc is a global biopharmaceutical
— Second Quarter Revenues of $399.1 Million — — Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income from Continuing Operations of $94.7 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.55 — — Company Reiterates 2024 Financial Expectations — DUBLIN, July 24, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the second quarter of 2024. "Our second quarter results reflect solid execution across our business, delivering double-digit, year-over-year growth for our proprietary commercial product portfolio and robust profitability. We enter the second half of the year in a strong
10-Q - Alkermes plc. (0001520262) (Filer)
8-K - Alkermes plc. (0001520262) (Filer)
8-K - Alkermes plc. (0001520262) (Filer)
Stifel upgraded Alkermes Plc from Hold to Buy and set a new price target of $36.00 from $25.00 previously
TD Cowen initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $34.00
Robert W. Baird initiated coverage of Alkermes Plc with a rating of Outperform and set a new price target of $37.00
DUBLIN, Nov. 11, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate at two upcoming investor conferences. Stifel Healthcare ConferenceDate/Time: Monday, Nov. 18, 2024 at 8:35 a.m. ET (1:35 p.m. GMT) Jefferies London Healthcare ConferenceDate/Time: Tuesday, Nov. 19, 2024 at 8:00 a.m. ET (1:00 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol depen
– 12 Poster Presentations Showcase Research in Schizophrenia, Bipolar I Disorder and Narcolepsy – – Results Presented From Real-World Retrospective Study of Healthcare Resource Utilization and Treatment Patterns in Patients With Schizophrenia or Bipolar I Disorder Following Initiation of LYBALVI®(olanzapine and samidorphan) – DUBLIN, Nov. 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the presentation of research related to LYBALVI® (olanzapine and samidorphan) and ARISTADA® (aripiprazole lauroxil), the company's commercial products in psychiatry, and ALKS 2680, an investigational medicine in development as a once-daily treatment for narcolepsy and idiopathic hypersomnia,
— Third Quarter Revenues of $378.1 Million — — Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $92.8 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.56 — — Company Reiterates 2024 Financial Expectations — DUBLIN, Oct. 24, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the third quarter of 2024. "Our third quarter financial results reflect strong year-over-year growth of our portfolio of proprietary commercial products and position us well to meet our strategic, operational and financial priorities for the year. Looking ahead, we believe growing our
Cantor Fitzgerald analyst Charles Duncan reiterates Alkermes (NASDAQ:ALKS) with a Overweight and maintains $48 price target.
JP Morgan analyst Jessica Fye maintains Alkermes (NASDAQ:ALKS) with a Neutral and raises the price target from $31 to $32.
Baird analyst Joel Beatty maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price target from $37 to $38.